The first study on the anti-phospholipid antibodies began in 1906 when Wasserman introduced a serological test for syphilis. In 1942 it was discovered that the active component is a phospholipid called Cardiolipina. In the 1950's it was observed that a large number of people appeared to be positive for syphilis tests but did not show any evidence of disease. Initially the phenomenon was classified as a series of false positive syphilis tests, before a more accurate analysis revealed, for this group of patients, a high prevalence of autoimmune disorders including SLE and Sjögrens syndrome.

The term lupus anticoagulant (LA), used for the first time in 1950's it was observed that a large number of people appeared to be positive for syphilis tests but did not show any evidence of disease. Initially the phenomenon was classified as a series of false positive syphilis tests, before a more accurate analysis revealed, for this group of patients, a high prevalence of autoimmune disorders including SLE and Sjögrens syndrome.

Some years later the role of a cofactor was investigated, the β2-glycoprotein I (apolipoprotein H) also called β2GPI, and its interactions with anionic phospholipids in human serum / plasma. This cofactor is a β-globulin with a molecular weight of 50 kDa that has a concentration of 200 μg / mL in plasma. The β2GPI is involved in the regulation of blood coagulation, inhibiting the intrinsic way. β2GPI in vivo is associated with negatively charged substances such as anionic phospholipids, heparin and lipoproteins. The region that binds phospholipids is in its fifth domain. The acronym "aPL" (anti-phospholipid antibodies) indicates improperly antibodies directed against negatively charged phospholipids like Cardiolipina (CL), Phosphatidyl serine (PS) Phosphatidyl inositol (PI) and phosphatidic acid (PA); more correctly the term anti-phospholipid antibodies indicates those antibodies directed against the complex between β2GPI and anionic phospholipids that can bind to the fifth domain of β2GPI. Among these, the Cardiolipina is the most commonly used phospholipid as an antigen for determining the aPL by ELISA method. Diagnostic laboratories measure the antibodies directed against the complex between β2GPI and negatively charged phospholipids, as Phosphatidyl serine (PS) Phosphatidyl inositol (PI) and phosphatidic acid (PA). Some researchers suggest the use of PS instead of Cardiolipina in ELISA assays, for a more precise diagnosis. However, these

antibodies against phospholipids are less commonly used, even if their use may increase the clinical sensitivity of patient samples with suspected

2. PRINCIPLE

Anti Cardiolipin IgG ELISA Assay Kit is based on the binding of antibodies on human serum or plasma directed against the antigenic complex between Cardiolipina and β2-Glycoprotein; this complex is coated on the microplate. In the first step the antibodies present in calibrators, controls or prediluted samples bind to this coated antigen. After a 60 minute incubation the microplate is washed with a wash buffer to remove the non-reactive serum or plasma components. Then an anti-human IgM horseradish peroxidase conjugated solution recognizes IgM class antibodies against the antigenic complex, which is not specifically bound, is washed away with the wash buffer. Finally, a chromogenic substrate solution containing TMB is dispensed into the wells. After a 15 minute incubation the color development is stopped by adding the stop solution. The solution turns yellow at this point. The level of color is directly proportional to the concentration of IgG antibodies present in the original sample. The concentration of IgG antibodies in the sample is calculated through a calibration curve.

3. REAGENTS, MATERIALS AND INSTRUMENTATION

3.1. Reagents and materials supplied in the kit

1. Anti Cardiolipin IgG Calibrators
   (5 vials, 1,2 mL each)
   Phosphate buffer 0,1M, NaNO₃ < 0,1%, human serum
   CAL0
   CAL1
   CAL2
   CAL3
   CAL4

2. Controls (2 vials, 1,2 mL each, ready for use)
   Phosphate buffer 0,1 M NaNO₃ < 0,1%, human serum
   Negative Control
   Positive Control

3. Sample Diluent (1 vial, 100 mL)
   Phosphate buffer 0,1M, NaNO₃ < 0,1%

4. Conjugate (1 vial, 15 mL)
   Anti h-IgG conjugate with horseradish peroxidase (HRP), BSA 0,1%, Proclin < 0,0015%

5. Coated Microplate
   (1 breakable microplate coated with antigenic Cardiolipina/β-2-Glycoprotein complex)
6. **TMB Substrate** (1 vial, 15 mL)
   - 3.3',5,5'-tetramethylbenzidine 0.26 g/L hydrogen peroxide 0.05%
   - **REF** DCE004-0

7. **Stop Solution** (1 vial, 15 mL)
   - Sulphuric acid 0.15M
   - **REF** DCE005-0

8. **10X Conc. Wash Solution** (1 vial, 50 mL)
   - Phosphate buffer 0.2M, procln < 0.0015%
   - **REF** DCE054-0

3.2. Reagents necessary not supplied
   - Distilled water.

3.3. Auxiliary materials and instrumentation
   - Automatic dispenser.
   - Microplate reader (450 nm).

4. **WARNINGS**
   - This Anti Cardiolipin IgG ELISA Assay Kit is intended for research use by professional persons only. Not for internal use on external use in Humans or Animals.
   - Use appropriate personal protective equipment while working with the reagents provided.
   - Follow Good Laboratory Practice (GLP) for handling blood products.
   - All human source material used in the preparation of the reagents in the Anti Cardiolipin IgG ELISA Assay Kit has been tested and found negative for antibody to HIV 1&2, HbsAg, and HCV. No test method however can offer complete assurance that HIV, HBV, HCV or other infectious agents are absent. Therefore, Calibrators and Controls should be handled in the same manner as potentially infectious material.
   - Material of animal origin used in the preparation of the kit has been obtained from animals certified as healthy and the bovine protein has been obtained from countries not infected by BSE, but these materials should be handled as potentially infectious.
   - Some reagents of the Anti Cardiolipin IgG ELISA Assay Kit contain small amounts of Sodium Azide (NaN₃) or Proclin 300⁰ as preservatives. Avoid the contact with skin or mucosa.
   - Sodium Azide may be toxic if ingested or absorbed through the skin or eyes; moreover it may react with lead or copper plumbing to form potentially explosive metal azides. If you use a sink to remove the reagents, allow scroll through large amounts of water to prevent azide build-up.
   - The TMB Substrate contains an irritant, which may be harmful if inhaled, ingested or absorbed through the skin. To prevent injury, avoid inhalation, ingestion or contact with skin and eyes.
   - The Stop Solution consists of a diluted sulphuric acid solution. Sulphuric acid is poisonous and corrosive and can be toxic if ingested. To prevent chemical burns, avoid contact with skin and eyes.
   - Avoid the exposure of reagent TMB/H₂O₂ to directed sunlight, metals or oxidants. Do not freeze the solution.

5. **PRECAUTIONS**
   - Please adhere strictly to the sequence of pipetting steps provided in this protocol. The performance data represented here were obtained using specific reagents listed in this Instruction For Use.
   - All reagents of the Anti Cardiolipin IgG ELISA Assay Kit should be stored refrigerated at 2-8°C in their original container. Any exceptions are clearly indicated. The reagents are stable until the expiry date when stored and handled as indicated.

   - Allow all Anti Cardiolipin IgG ELISA Assay Kit components and specimens to reach room temperature (22-28°C) and mix well prior to use.
   - Do not interchange Anti Cardiolipin IgG ELISA Assay Kit components from different lots. The expiry date printed on box and vials labels must be observed. Do not use any kit component beyond their expiry date.

**WARNING:** the conjugate reagent is designed to ensure maximum dose sensitivity and may be contaminated by external agents if not used properly; therefore, it is recommended to use disposable consumables (tips, bottles, trays, etc.). For divided doses, take the exact amount of conjugate needed and do not re-introduce any waste product into the original bottle. In addition, **for doses dispensed with the aid of automatic and semi-automatic devices**, before using the conjugate, it is advisable to clean the fluid handling system, ensuring that the procedures of washing, deproteinization and decontamination are effective in avoiding contamination of the conjugate; this procedure is highly recommended when the kit is processed using analyzers which are not equipped with disposable tips.

   - If you use automated equipment, the user has the responsibility to make sure that the kit has been appropriately tested.
   - The incomplete or inaccurate liquid removal from the wells could influence the assay precision and/or increase the background.
   - It is important that the time of reaction in each well is held constant for reproducible results. Pipetting of samples should not extend beyond ten minutes to avoid assay drift. If more than 10 minutes are needed, follow the same order of dispensation. If more than one plate is used, it is recommended to repeat the dose response curve in each plate.

   - Addition of the TMB Substrate solution initiates a kinetic reaction, which is terminated by the addition of the Stop Solution. Therefore, the TMB Substrate and the Stop Solution should be added in the same sequence to eliminate any time deviation during the reaction.

   - Observe the guidelines for performing quality control in medical laboratories by assaying controls and/or pooled sera.

   - Maximum precision is required for reconstitution and dispensation of the reagents.

   - Samples microbiologically contaminated, highly lipemic or haemolysed should not be used in the assay.

   - Plate readers measure vertically. Do not touch the bottom of the wells.

6. **PROCEDURE**

6.1. **Preparation of Calibrators (C₀...C₄)**
   - The Calibrators are ready to use and have approximately the following concentrations:
   - **AU/mL**
     - C₀: 0
     - C₁: 5
     - C₂: 10
     - C₃: 20
     - C₄: 80
   - Once opened, the Calibrators are stable 6 months at 2-8°C.

6.2. **Sample Preparation**
   - Either human serum or plasma samples can be used for the test execution. Test samples should be clear. Contamination by lipemia is best avoided, but does not interfere with this assay. Specimens may be refrigerated at 2-8°C for up to five days or stored at -20°C up to six months. Avoid repetitive freezing and thawing of serum.
samples. This may result in variable loss of autoantibody activity. Testing of heat-inactivated sera is not recommended.

All serum and plasma samples have to be diluted 1:100 with sample diluent; for example 10 μL of sample should be diluted to 1,000 μL with sample diluent. The Controls are ready to use.

6.3. Wash Solution Preparation

Dilute the contents of each vial of the buffered wash solution concentrate (10X) with distilled water to a final volume of 500 mL prior to use. For smaller volumes respect the 1:10 dilution ratio. The diluted wash solution is stable for 30 days at 2-8°C.

In concentrated wash solution it is possible to observe the presence of crystals. In this case mix at room temperature until complete dissolution of crystals is observed. For greater accuracy dilute the whole bottle of concentrated wash solution to 500 mL taking care also to transfer the crystals completely, then mix until the crystals are completely dissolved.

6.4. Procedure

- Allow all reagents to reach room temperature (22-28°C) for at least 30 minutes.
- Unused coated microwell strips should be released securely in the foil pouch containing desiccant and stored at 2-8°C.
- To avoid potential microbial and/or chemical contamination, unused reagents should never be transferred into the original vials.
- As it is necessary to perform the determination in duplicate in order to improve accuracy of the test results, prepare two wells for each point of the calibration curve (C₀-C₄), two for each Control, two for each sample, one for Blank.

<table>
<thead>
<tr>
<th>Reagents</th>
<th>Calibrator</th>
<th>Sample/ Controls</th>
<th>Blank</th>
</tr>
</thead>
<tbody>
<tr>
<td>Calibrator C₀-C₄</td>
<td>100 μL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Controls</td>
<td>100 μL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diluted Sample</td>
<td>100 μL</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Incubate for 60 minutes at room temperature (22-28°C). Remove the content from each well, wash the wells 3 times with 300 μL of diluted wash solution.

<table>
<thead>
<tr>
<th>Conjugate</th>
<th>100 μL</th>
<th>100 μL</th>
</tr>
</thead>
</table>

Incubate for 60 minutes at room temperature (22-28°C). Remove the content from each well, wash the wells 3 times with 300 μL of diluted wash solution.

<table>
<thead>
<tr>
<th>TMB Substrate</th>
<th>100 μL</th>
<th>100 μL</th>
<th>100 μL</th>
</tr>
</thead>
</table>

Incubate for 15 minutes in the dark at room temperature (22-28°C).

<table>
<thead>
<tr>
<th>Stop Solution</th>
<th>100 μL</th>
<th>100 μL</th>
<th>100 μL</th>
</tr>
</thead>
</table>

Shake the microplate gently. Read the absorbance (E) at 450 nm against Blank within 5 minutes.

7. QUALITY CONTROL

- The Anti Cardiolipin IgG Positive and Negative Control should be run with every batch of samples to ensure that all reagents and procedures perform properly.
- Because the Positive and Negative Controls are prediluted, do not use procedural methods associated with dilution of specimens.
- Additional suitable control sera may be prepared by aliquoting pooled human serum specimens and storing at < -20°C.
- For best results, all of the criteria listed below must be met. If any of these are not met, the test should be considered invalid and the assay repeated:
  - The Positive and Negative Controls are intended to monitor for substantial reagent failure and they will not ensure precision at the assay cut-off.
  - This test is only valid if the optical density at 450 nm for the Positive Control as well as for the Calibrators (C₀-C₄) complies with the respective range indicated on the Quality Control Certificate enclosed in each test kit.

8. RESULTS

For Anti Cardiolipin IgG test a 4-Parameter-Fit with lin-log coordinates for optical density and concentration is the data reduction method of choice. Smoothed-Spline Approximation and log-log coordinates are also suitable. However a Lin-Log Plot is recommended.

First calculate the average optical densities for each calibrator well. Use lin-log graph paper and plot the averaged optical density of each calibrator versus the concentration. Draw the best fitting curve approximating the path of all calibrator points. The calibrator points may also be connected with straight line segments. The concentration of unknowns may then be estimated from the calibration curve by interpolation.

9. REFERENCE VALUES

In a normal range study with serum samples from healthy blood donors the following ranges have been established with the Anti-Cardiolipina IgG test:

<table>
<thead>
<tr>
<th>Anti Cardiolipin IgG (AU/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal</td>
</tr>
<tr>
<td>≤ 10</td>
</tr>
<tr>
<td>Elevated</td>
</tr>
<tr>
<td>≥ 10</td>
</tr>
</tbody>
</table>

Please pay attention to the fact that the determination of a range of expected values for a “normal” population in a given method is dependent on many factors, such as specificity and sensitivity of the method used and type of population under investigation. Therefore each laboratory should consider the range given by the Manufacurer as a general indication and produce their own range of expected values based on the indigenous population where the laboratory works.

It is recommended that each laboratory establishes its own normal and pathological ranges of seric Ab-Anti-Cardiolipina.

10. LIMITATIONS OF PROCEDURE

The presence of immune complexes or other immunoglobin aggregates in the sample may cause an increased level of non-specific binding and produce false positives in this assay.
11. PERFORMANCE AND CHARACTERISTICS

11.1. Precision and reproducibility

Precision and reproducibility are evaluated by two positive samples tested in two different runs with two different lots. Dispensing and washing operations were performed manually by an operator. The results in terms of standard deviation and coefficient of variation are below:

<table>
<thead>
<tr>
<th>Sample</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>SD</td>
<td>CV%</td>
</tr>
<tr>
<td>Intra-assay</td>
<td>2.73</td>
<td>5.6</td>
</tr>
<tr>
<td>Inter-assay</td>
<td>0.15</td>
<td>7.3</td>
</tr>
</tbody>
</table>

11.2. Sensitivity

Test against a commercial reference kit, performed on 58 sera (including 23 positive sera and 35 negative sera) showed a sensitivity of 75.0%.

11.3. Specificity

Test against a commercial reference kit, performed on 58 sera (including 23 positive and 35 negative sera) showed a specificity of 70.0%.

11.4. Detection Limit

The lowest concentration of antibodies Anti Cardiolipin IgG that can be distinguished from Calibrator zero is about 0.08 AU/mL with a confidence limit of 95%.

12. WASTE MANAGEMENT

Reagents must be disposed off in accordance with local regulations.

BIBLIOGRAPHY